In vitro study reveals that plasma-activated saline enhances cisplatin efficacy in resistant bladder cancer cells, indicating potential treatment improvements.
Plasma‐activated saline (PAS) loads reactive oxygen and nitrogen species, triggering oxidative stress and tumor death. However, PAS exhibits poor anticancer efficacy due to rapid dilution and reactive species decay. Herein, we developed a plasma bubble reactor to activate saline and investigate its synergy with cisplatin (DDP) against DDP‐resistant T24 bladder cancer cells (T24/DDP) in vitro. The results showed that PAS‐DDP significantly reduced the cell viability of T24/DDP to 32.4%, surpassing PAS (52.9%) or DDP alone (96.9%). PAS‐DDP significantly inhibited T24/DDP cells by intracellular reactive oxygen species accumulation, mitochondrial depolarization, and cell apoptosis induction. Moreover, PAS‐DDP suppressed the p62/Keap1/Nrf2 signaling pathway, restoring oxidative sensitivity and boosting DDP efficacy. These findings suggest that PAS could enhance chemotherapy efficacy and overcome drug resistance.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: